Amgen Inc SEC filings AMGN
Amgen Inc has 1,000 filings in SEC EDGAR's recent list, going back to May 22, 2018. Its latest annual report, Form ARS, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| DEFA14A | Additional proxy material | Apr 15, 2026 | — |
| DEFA14A | Additional proxy material | Apr 7, 2026 | — |
| DEF 14A | Proxy statement | Apr 7, 2026 | May 19, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEFA14A | Additional proxy material | Apr 17, 2025 | — |
| DEFA14A | Additional proxy material | Apr 9, 2025 | — |
| DEF 14A | Proxy statement | Apr 9, 2025 | May 23, 2025 |
| DEFA14A | Additional proxy material | May 10, 2024 | — |
| DEFA14A | Additional proxy material | May 3, 2024 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEFA14A | Additional proxy material | Apr 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 17, 2024 | May 31, 2024 |
| DEFA14A | Additional proxy material | May 3, 2023 | — |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEF 14A | Proxy statement | Apr 6, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEFA14A | Additional proxy material | Apr 22, 2022 | — |
| DEFA14A | Additional proxy material | Apr 13, 2022 | — |
| DEFA14A | Additional proxy material | Apr 5, 2022 | — |
| DEF 14A | Proxy statement | Apr 5, 2022 | May 17, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEFA14A | Additional proxy material | Apr 14, 2021 | — |
| DEFA14A | Additional proxy material | Apr 6, 2021 | — |
| DEF 14A | Proxy statement | Apr 6, 2021 | May 18, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEFA14A | Additional proxy material | Apr 13, 2020 | — |
| DEFA14A | Additional proxy material | Apr 7, 2020 | — |
| DEF 14A | Proxy statement | Apr 7, 2020 | May 19, 2020 |
| DEFA14A | Additional proxy material | May 13, 2019 | — |
| DEFA14A | Additional proxy material | May 2, 2019 | — |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEFA14A | Additional proxy material | Apr 22, 2019 | — |
| DEFA14A | Additional proxy material | Apr 8, 2019 | — |
| DEF 14A | Proxy statement | Apr 8, 2019 | May 21, 2019 |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AMGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Thousand Oaks, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 318154
Other Biological Products, (No Diagnostic Substances) companies
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.